- Conditions
- Cataract, IOL, Glaucoma, Open-Angle
- Interventions
- Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold
- Procedure
- Lead sponsor
- Vold Vision P.L.L.C
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 2,409
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
- Interventions
- Ruvidar® (TLD-1433) bladder infusion and PDT
- Combination Product
- Lead sponsor
- Theralase® Technologies Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more
- Conditions
- Periorbital Wrinkles, Periorbital Area, Under-eyes Dark Circles, Crows Feet
- Interventions
- Treatment with BTL-785 with the applicator BTL-785-7-11
- Device
- Lead sponsor
- BTL Industries Ltd.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Sacramento, California • Solana Beach, California • Youngstown, Ohio
- Conditions
- Degenerative Disc Disease
- Interventions
- Not listed
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
- Interventions
- Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Pembrolizumab, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
- Drug
- Lead sponsor
- Baylor Breast Care Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Gynecologic Disease
- Interventions
- Bowel Preparation, No bowel preparation
- Other
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Warren, Michigan
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1006
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Aspergillosis Invasive
- Interventions
- Isavuconazonium Injection [Cresemba], Placebo
- Drug
- Lead sponsor
- Jeffrey Jenks, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 3
- States / cities
- Orange, California • Sacramento, California • San Diego, California
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Arzoxifene, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years · Female only
- Enrollment
- 9,369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Elk Grove, Illinois
- Conditions
- Aneuploidy, Trisomy 21, Trisomy 18, Trisomy 13, Down Syndrome
- Interventions
- Not listed
- Lead sponsor
- Cindy Cisneros
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- San Diego, California • Oaks, Pennsylvania • Chattanooga, Tennessee
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT), quality-of-life assessment
- Combination Product · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Urothelial Cancer, Urinary Bladder Neoplasms
- Interventions
- Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab
- Drug · Radiation
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Santa Barbara, California • Aurora, Colorado + 18 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
- Interventions
- Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2035
- U.S. locations
- 1160
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more
- Conditions
- Portal Hypertension, Chronic Liver Disease
- Interventions
- ARFI ultrasound
- Device
- Lead sponsor
- VA Connecticut Healthcare System
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • West Haven, Connecticut
- Conditions
- Staphylococcus Aureus
- Interventions
- Targeted gown and glove use
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Belcamp, Maryland • Lutherville-Timonium, Maryland
- Conditions
- Hydrocephalus in Infants
- Interventions
- Non-Invasive Pressure Monitor
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 0 Months to 12 Months
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Sensorineural Hearing Loss, Bilateral Hearing Loss, Cochlear Implantation, Hearing Disorders, Hearing Disorders and Deafness, Inner Ear Disorders, Hearing Impairment
- Interventions
- IotaSoft Robotic Insertion System, Manual Cochlear Implant Insertion
- Device · Procedure
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Kissimmee, Florida
- Conditions
- Hypoxia
- Interventions
- Non-Invasive Controlled Hypoxia
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Louisville, Colorado
- Conditions
- Invasive Breast Cancer
- Interventions
- [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma
- Interventions
- Bexarotene, Questionnaire Administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Invasive Carcinoma, In Situ Carcinoma, Fibrocystic Changes, Atypical Ductal Hyperplasia
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Invasive Bladder Cancer
- Interventions
- Cystectomy, Lidocaine, Saline
- Procedure · Drug
- Lead sponsor
- CAMC Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Charleston, West Virginia
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Hippel-Landau Disease, Mitochondria
- Interventions
- Feasibility Study - Imaging System
- Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neuromuscular Diseases, Healthy Volunteers
- Interventions
- pneuRIP (breathing with resistance), Respitrace system (Carefusion) (breathing without resistance)
- Device
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware